Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04042311
Other study ID # R2219
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 15, 2018
Est. completion date December 28, 2022

Study information

Verified date November 2022
Source Hull University Teaching Hospitals NHS Trust
Contact Sean Pymer, MSc
Phone 01482 674643
Email sean.pymer@hey.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This INITIATE study evaluates the use of high-intensity interval training as a treatment modality for patients with intermittent claudication - an ambulatory leg pain caused by narrowed arteries that supply the lower limbs. It is an observational cohort study considering HIIT as a treatment for intermittent claudication, consisting of two workstreams. Workstream 1: an initial observational cohort study to consider the feasibility of the intervention and exclusion criteria. Workstream 2: a proof of concept study utilising the altered intervention and exclusion criteria following recommendations highlighted during workstream 1.


Description:

Patients with peripheral vascular disease (PVD) may develop a reproducible pain in their legs when they walk, which usually subsides with rest. This is known as intermittent claudication (IC) and is caused by a reduced blood supply to the legs as a result of narrowed or hardened arteries that supply the lower limbs. This ambulatory pain impedes on activities of daily living, functional capacity and quality of life. NICE clinical guidance recommends a 12-week supervised exercise programme as first-line treatment for IC, whereby patients are encouraged to walk to the point of maximal pain. Robust clinical trials have demonstrated that supervised exercise programmes are efficacious for improving both pain-free and maximal walking distances, whilst also potentially improving quality of life. Despite this, supervised exercise programmes are vastly under-utilised and not always available to consultant vascular surgeons. This means that further programmes need to be developed in order to provide a range of options to patients to improve uptake and adherence rates. One such programme is a 6-week high-intensity interval training programme. An initial observational cohort study of the 6 week HIIT programme will be conducted to determine to determine the feasibility of the intervention and inclusion criteria. The results from this will be used to make any necessary changes to the HIIT intervention before moving into a proof of concept study, considering the utility, safety, acceptability and potential clinical efficacy of this programme.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 28, 2022
Est. primary completion date October 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Workstream 1 Inclusion criteria: - Aged >18 years - ABPI <0.9 at rest or a systolic pressure drop of =20mmHg at the ankle after exercise testing - Ability to walk unaided - English speaking and able to comply with exercise instructions Exclusion criteria: - Unable to provide informed consent - Critical limb threatening ischaemia / rest pain / tissue loss - Active cancer treatment - Significant comorbidities precluding safe participation in exercise testing and / or training according to the American College of Sports Medicine (ACSM) guidelines (28) - Resting/uncontrolled tachycardia (>100bpm) and/or resting/uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure >100mmHg) - Symptomatic hypotension Additional exclusion criteria: Following baseline CPET, patients will be withdrawn and prevented from continuing their involvement in the study if there is any evidence of: - Exercise-induced myocardial ischaemia or significant haemodynamic compromise (manifesting as anginal symptoms, significant ECG changes or an abnormal blood pressure response). - An inability to complete a maximal effort CPET Workstream 2: Inclusion criteria: - Aged >18 years - ABPI <0.9 at rest or a systolic pressure drop of =20mmHg at the ankle after exercise testing - Ability to walk unaided - English speaking and able to comply with exercise instructions Exclusion criteria: - Unable to provide informed consent - Critical limb threatening ischaemia / rest pain / tissue loss - Active cancer treatment - Significant comorbidities precluding safe participation in exercise testing and / or training according to the American College of Sports Medicine (ACSM) guidelines (28) - Resting/uncontrolled tachycardia (>100bpm) and/or resting/uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure >100mmHg) - Symptomatic hypotension Additional exclusion criteria: Following baseline CPET, patients will be withdrawn and prevented from continuing their involvement in the study if there is any evidence of: ? Exercise-induced myocardial ischaemia or significant haemodynamic compromise (manifesting as anginal symptoms, significant ECG changes or an abnormal blood pressure response).

Study Design


Intervention

Other:
High-intensity interval training
a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.

Locations

Country Name City State
United Kingdom Academic Vascular Surgical Unit, Vascular Dept. 1st Floor Tower Block Hull

Sponsors (2)

Lead Sponsor Collaborator
Hull University Teaching Hospitals NHS Trust University of Hull

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Pymer S, Palmer J, Harwood AE, Ingle L, Smith GE, Chetter IC. A systematic review of high-intensity interval training as an exercise intervention for intermittent claudication. J Vasc Surg. 2019 Dec;70(6):2076-2087. doi: 10.1016/j.jvs.2019.03.050. Epub 20 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Events Recorded Defined as the occurrence of any adverse or serious adverse events. From enrolment to completion of 12-week follow-up
Primary Tolerability Test Defined by examining the patients ability to achieve and maintain exercise at the appropriate intensity for the duration of each session and examining reasons for withdrawal and whether or not they were related to the intervention. Tolerability will also consider the number of patients able to achieve a maximal effort CPET. From the first to last exercise session, i.e. from week 0 to week 6.
Primary Feasibility Test Feasibility measures included the number of patients screened vs. the number eligible, the number of patients eligible vs. the number recruited and the number recruited vs. the number completed. From study opening to recruitment to completion of last patient last visit i.e. 29 weeks
Secondary Acceptability testing An evaluation of the acceptability of the exercise intervention assessed by patient feedback, using semi-structured interviews. post-intervention follow-up, i.e. week 6.
Secondary Maximum walking distance assessment of the distance that the patient can currently walk before having to stop due to claudication pain. Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
Secondary Pain-free walking distance assessment of the distance that the patient can currently walk before experiencing claudication pain. Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
Secondary Physiological parameters Physiological variables via cardiopulmonary exercise test to assess peak oxygen uptake and ventilatory anaerobic threshold Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
Secondary Quality of Life Questionnaire SF-36 Patient reported quality of life using the SF-36 SF-36 is a 36-Item Short Form Health Survey questionnaire. It consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
Secondary Quality of Life Questionnaire - VascuQol Patient reported quality of life using VascuQoL VascuQol is a Vascular specific QoL tool, It measures across 4 domains and gives a total score ranging from 0-7 with a higher score indicating better Vascular specific quality of life. Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
Secondary Ankle-Brachial Pressure Index The index or ratio of the pressure in the ankle compared with the arm. Baseline, post-intervention (week 6), then 4 weeks (week 10) and 12 weeks (week 18) post-intervention.
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1